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Background: Depression is a common co-morbid condition which can increase the risk of death and hospitalization of patients with heart failure 
(HF), yet the mechanisms linking the two conditions are not clearly understood. Treatment strategies aimed to reduce depression in HF patients are 
still sparse and certain therapies, such as beta blockade may worsen depression. This study examines the link between catecholamine levels and 
depression scores and their change with treatment with renin-angiotensin antagonists and beta blockade.
Methods: This is a substudy of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD). The original study randomized 
patients with clinical signs and symptoms of HF, a six minute walk test of ≤500 meters and an ejection fraction of ≤40% to receive either enalapril, 
candesartan or both in the first phase. In phase II, patients from each group were then randomized to either metoprolol or placebo. In this substudy, 
depression scores were obtained through the Beck Depression Inventory (BDI) at baseline and at the end of each stage. Norepinephrine levels were 
analyzed and compared at every phase of the study.
Results: In total 315 patients had baseline BDI scores. Patients with BDI scores <10 (indicating no depression or mild depression), were more 
likely to be younger, male, and diabetic with lower Minnesota Living with Heart Failure Quality of Life scores, greater 6-minute walk distance and 
lower NYHA class. There was no correlation between BDI scores and norepinephrine levels, at baseline, end of phase I or end of phase II. There were 
no associations between change in BDI scores across each phase and change in norepinephrine levels. There is no correlation between depression 
scores and norepinephrine levels at baseline and with treatment with renin-angiotensin antagonists or with beta blockade.
Conclusions: Although the results do not help explain the postulated association between depression and heart failure, it provides reassurance to 
clinicians that treatment strategies aimed at reducing heart failure mortality do not lead to increased depression scores.
